Svaton M - Search Results

1

Prognostic Significance of Serum Tumor Markers in Patients with Advanced-stage NSCLC Treated with Pemetrexed-based Chemotherapy.

Fiala O, Pesek M, Finek J, Svaton M, Sorejs O, Bortlicek Z, Kucera R, Topolcan O. Fiala O, et al. Among authors: svaton m. Anticancer Res. 2016 Jan;36(1):461-6. Anticancer Res. 2016. PMID: 26722082

2

Predictive and prognostic significance of sodium levels in patients with NSCLC treated by erlotinib.

Svaton M, Fiala O, Pesek M, Bruha F, Mukensnabl P, Racek J, Minarik M, Bortlicek Z. Svaton M, et al. Anticancer Res. 2014 Dec;34(12):7461-5. Anticancer Res. 2014. PMID: 25503188

3

Current two EGFR mutations in lung adenocarcinoma - case report.

Svaton M, Pesek M, Chudacek Z, Vosmiková H. Svaton M, et al. Klin Onkol. 2015;28(2):134-7. Klin Onkol. 2015. PMID: 25882025

4

Pemetrexed Versus Erlotinib in the Second-line Treatment of Patients with Advanced-stage Non-squamous NSCLC Harboring Wild-type EGFR Gene.

Fiala O, Pesek M, Finek J, Svaton M, Minarik M, Benesova L, Bortlicek Z, Kucera R, Topolcan O. Fiala O, et al. Among authors: svaton m. Anticancer Res. 2016 Jan;36(1):447-53. Anticancer Res. 2016. PMID: 26722080

5

Epidermal Growth Factor Receptor Gene Amplification in Patients with Advanced-stage NSCLC.

Fiala O, Pesek M, Finek J, Minarik M, Benesova L, Sorejs O, Svaton M, Bortlicek Z, Kucera R, Topolcan O. Fiala O, et al. Among authors: svaton m. Anticancer Res. 2016 Jan;36(1):455-60. Anticancer Res. 2016. PMID: 26722081

6

[Successful Therapy of Czech Patients with ROS1 Translocation by Crizotinib].

Svaton M, Pešek M. Svaton M, et al. Klin Onkol. 2016;29(1):63-5. doi: 10.14735/amko201663. Klin Onkol. 2016. PMID: 26879065 Czech.

7

The Prognostic Role of KRAS Mutation in Patients with Advanced NSCLC Treated with Second- or Third-line Chemotherapy.

Svaton M, Fiala O, Pesek M, Bortlicek Z, Minarik M, Benesova L, Topolcan O. Svaton M, et al. Anticancer Res. 2016 Mar;36(3):1077-82. Anticancer Res. 2016. PMID: 26977001

8

Change in Serum Lactate Dehydrogenase Is Associated with Outcome of Patients with Advanced-stage NSCLC Treated with Erlotinib.

Fiala O, Pesek M, Finek J, Topolcan O, Racek J, Svaton M, Kucera R, Minarik M, Benesova L, Bortlicek Z, Chloupkova R, Poprach A, Buchler T. Fiala O, et al. Among authors: svaton m. Anticancer Res. 2016 May;36(5):2459-65. Anticancer Res. 2016. PMID: 27127158

9

Thyroid transcription factor 1 expression is associated with outcome of patients with non-squamous non-small cell lung cancer treated with pemetrexed-based chemotherapy.

Fiala O, Pesek M, Skrickova J, Kolek V, Salajka F, Tomiskova M, Satankova M, Kultan J, Kuliskova J, Svaton M, Hrnciarik M, Hejduk K, Chloupkova R, Topolcan O, Hornychova H, Nova M, Ryska A, Finek J. Fiala O, et al. Among authors: svaton m. Tumour Biol. 2017 Feb;39(2):1010428317691186. doi: 10.1177/1010428317691186. Tumour Biol. 2017. PMID: 28218046 Free article.

10

Predictive Significance of Thymidylate Synthase Expression in Non-small Cell Lung Cancer.

Kulda V, Hrda K, Houdek Z, Dobra JK, Vrzakova R, Svaton M, Safranek J, Dolezal J, Babuska V, Pesek M, Topolcan O, Pesta M. Kulda V, et al. Among authors: svaton m. Anticancer Res. 2017 Dec;37(12):6953-6958. doi: 10.21873/anticanres.12161. Anticancer Res. 2017. PMID: 29187479

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

81 results

Search Page

Filters